A multi-institutional study to assess adherence to lung stereotactic body radiotherapy planning goals

被引:6
|
作者
Woerner, Andrew [1 ]
Roeske, John C. [1 ]
Harkenrider, Matthew M. [1 ]
Fan, John [2 ]
Aydogan, Bulent [3 ]
Koshy, Matthew [3 ]
Laureckas, Robert [4 ]
Vali, Faisal [4 ]
Campana, Maria [1 ]
Surucu, Murat [1 ]
机构
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[2] Edward Canc Ctr, Naperville, IL 60540 USA
[3] Univ Illinois, Dept Radiat Oncol, Chicago, IL 60612 USA
[4] Advocate Christ Med Ctr, Oak Lawn, IL 60453 USA
关键词
stereotactic body radiotherapy; SBRT; SABR; lung cancer; conformality; THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; RESECTION; OUTCOMES;
D O I
10.1118/1.4926551
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: A multi-institutional planning study was performed to evaluate the frequency that current guidelines established by Radiation Therapy Oncology Group (RTOG) protocols and other literature for lung stereotactic body radiotherapy (SBRT) treatments are followed. Methods: A total of 300 patients receiving lung SBRT treatments in four different institutions were retrospectively reviewed. The treatments were delivered using Linac based SBRT (160 patients) or image guided robotic radiosurgery (140). Most tumors were located peripherally (250/300). Median fractional doses and ranges were 18 Gy (8-20 Gy), 12 Gy (6-15 Gy), and 10 Gy (5-12 Gy) for three, four, and five fraction treatments, respectively. The following planning criteria derived from RTOG trials and the literature were used to evaluate the treatment plans: planning target volumes, PTVV100 >= 95% and PTVV95 >= 99%; conformality indices, CI100% < 1.2 and CI50% range of 2.9-5.9 dependent on PTV; total lung-ITV: V-20Gy < 10%, V-12.5Gy < 15%, and V-5Gy < 37%; contralateral lung V-5Gy < 26%; and maximum doses for spinal cord, esophagus, trachea/bronchus, and heart and great vessels. Populations were grouped by number of fractions, and dosimetric criteria satisfaction rates (CSRs) were reported. Results: Five fraction regimens were the most common lung SBRT fractionation (46%). The median PTV was 27.2 cm(3) (range: 3.8-419.5 cm(3)). For all plans: mean PTVV100 was 94.5% (+/- 5.6%, planning CSR: 69.8%), mean PTVV95 was 98.1% (+/- 4.1%, CSR: 69.5%), mean CI100% was 1.14 (+/- 0.21, CSR: 79.1%, and 16.5% within minor deviation), and mean CI50% was 5.63 (+/- 2.8, CSR: 33.0%, and 28.0% within minor deviation). When comparing plans based on location, peripherally located tumors displayed higher PTVV100 and PTVV95 CSR (71.5% and 71.9%, respectively) than centrally located tumors (61.2% and 57.1%, respectively). Overall, the planning criteria were met for all the critical structure such as lung, heart, spinal cord, esophagus, and trachea/bronchus for at least 85% of the patients. Conclusions: Among the various parameters that were used to evaluate the SBRT plans, the CI100% and CI50% were the most challenging criteria to meet. Although the CSRs of organs at risk were higher among all cases, their proximity to the PTV was a significant factor. (C) 2015 American Association of Physicists in Medicine.
引用
收藏
页码:4629 / 4635
页数:7
相关论文
共 50 条
  • [41] Stereotactic radiosurgery for clinoid meningiomas: a multi-institutional study
    Bunevicius, Adomas
    Pikis, Stylianos
    Anand, Rithika Kormath
    Nabeel, Ahmed M.
    Reda, Wael A.
    Tawadros, Sameh R.
    Abdelkarim, Khaled
    El-Shehaby, Amr M. N.
    Emad, Reem M.
    Chytka, Tomas
    Liscak, Roman
    Caceres, Marco Perez
    Mathieu, David
    Lee, Cheng-Chia
    Yang, Huai-Che
    Picozzi, Piero
    Franzini, Andrea
    Attuati, Luca
    Speckter, Herwin
    Olivo, Jeremy
    Patel, Samir
    Cifarelli, Christopher P.
    Cifarelli, Daniel T.
    Hack, Joshua D.
    Strickland, Ben A.
    Zada, Gabriel
    Chang, Eric L.
    Fakhoury, Kareem R.
    Rusthoven, Chad G.
    Warnick, Ronald E.
    Sheehan, Jason
    ACTA NEUROCHIRURGICA, 2021, 163 (10) : 2861 - 2869
  • [42] Stereotactic radiosurgery for clinoid meningiomas: a multi-institutional study
    Adomas Bunevicius
    Stylianos Pikis
    Rithika Kormath Anand
    Ahmed M. Nabeel
    Wael A. Reda
    Sameh R. Tawadros
    Khaled Abdelkarim
    Amr M. N. El-Shehaby
    Reem M. Emad
    Tomas Chytka
    Roman Liscak
    Marco Perez Caceres
    David Mathieu
    Cheng-chia Lee
    Huai-che Yang
    Piero Picozzi
    Andrea Franzini
    Luca Attuati
    Herwin Speckter
    Jeremy Olivo
    Samir Patel
    Christopher P. Cifarelli
    Daniel T. Cifarelli
    Joshua D. Hack
    Ben A. Strickland
    Gabriel Zada
    Eric L. Chang
    Kareem R. Fakhoury
    Chad G. Rusthoven
    Ronald E. Warnick
    Jason Sheehan
    Acta Neurochirurgica, 2021, 163 : 2861 - 2869
  • [43] A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma
    Herman, Joseph M.
    Chang, Daniel Tandel
    Goodman, Karyn A.
    Wild, Aaron Tyler
    Laheru, Dan
    Zheng, Lei
    Diaz, Luis A.
    Dung Thi Le
    Raman, Siva P.
    Leal, Jeffrey P.
    Chaudhry, Muhammad Ali
    Sugar, Elizabeth
    Columbo, Laurie Ann
    Tom, Ashlyn
    Limaye, Maneesha R.
    Edil, Barish H.
    Oteiza, Katharine
    Hacker-Prietz, Amy
    Wolfgang, Christopher Lee
    Koong, Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study
    Aoki, Masahiko
    Hatayama, Yoshiomi
    Kawaguchi, Hideo
    Hirose, Katsumi
    Sato, Mariko
    Akimoto, Hiroyoshi
    Miura, Hiroyuki
    Ono, Shuichi
    Takai, Yoshihiro
    JOURNAL OF RADIATION RESEARCH, 2016, 57 (01) : 55 - 61
  • [45] A multi-institutional predicting nomogram for BCLC stage C hepatocellular carcinoma after stereotactic body radiotherapy.
    Huang, Wen-Yen
    Lin, Yu-Ju
    Cheng, Jason C.
    Que, Jenny
    Lee, Mei-Hsuan
    Tsai, Chiao-Ling
    Lo, Cheng-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy.
    Jiang, Naomi Y.
    King, Christopher R.
    Katz, Alan J.
    Collins, Sean P.
    Aghdam, Nima
    Suy, Simeng
    Stephans, Kevin L.
    Reddy, Chandana A.
    Kaplan, Irving D.
    Appelbaum, Limor
    Dang, Audrey
    Yuan, Ye
    Nickols, Nicholas George
    Steinberg, Michael L.
    Kupelian, Patrick
    Kishan, Amar Upadhyaya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [47] AI-based radiotherapy treatment planning quality assurance: A multi-institutional study
    Kalendralis, P.
    Luk, S. M.
    Canters, R.
    Eyssen, D.
    Vaniqui, A.
    Wolfs, C.
    Murrer, L.
    van Elmpt, W.
    Kalet, A. M.
    Dekker, A.
    van Soest, J.
    Fijten, R.
    Zegers, C. M.
    Bermejo, I.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S243 - S244
  • [48] Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer A Multi-Institutional Analysis
    Harkenrider, Matthew M.
    Bertke, Matthew H.
    Dunlap, Neal E.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (04): : 337 - 342
  • [49] Long-term efficacy of stereotactic body radiotherapy for localized prostate cancer: A multi-institutional pooled analysis
    Kupelian, Patrick
    Katz, Alan J.
    Freeman, Debra
    Kaplan, Irving D.
    Fuller, Donald B.
    Bolzicco, Giampaolo
    Collins, Sean P.
    Meier, Robert
    Wang, Jason
    King, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [50] Dose calculation accuracies in whole breast radiotherapy treatment planning: a multi-institutional study
    Hatanaka S.
    Miyabe Y.
    Tohyama N.
    Kumazaki Y.
    Kurooka M.
    Okamoto H.
    Tachibana H.
    Kito S.
    Wakita A.
    Ohotomo Y.
    Ikagawa H.
    Ishikura S.
    Nozaki M.
    Kagami Y.
    Hiraoka M.
    Nishio T.
    Radiological Physics and Technology, 2015, 8 (2) : 200 - 208